By William Sumner, Hemp Business Journal Contributor Last week, the hemp industry was abuzz with the news that the United States Drug Enforcement Administration (DEA) would move Epidiolex, a CBD-based drug derived from cannabis, from a Schedule I substance to a Schedule V substance. The scheduling does not explicitly pertain to CBD, but it does […]

By William Sumner, Hemp Business Journal Contributor Pending word at any time, the United States Drug Enforcement Administration (DEA) is expected to reschedule Epidiolex, a CBD-based drug derived from cannabis. An announcement was due on Sept. 23, but by press time remained forthcoming. Manufactured by the London-based GW Pharmaceuticals, the drug has been shown to […]

By William Sumner, Hemp Business Journal Contributor The potential both practical and profitable for cannabidiol (CBD) has been gaining an increasing amount of national attention. From alleviating intractable seizures to soothing anxiety, CBD’s health benefits have (anecdotally) become well known, which has translated to millions of dollars’ worth of investment from entrepreneurs and [...]

By William Sumner, Hemp Business Journal Contributor It has been a busy, yet quiet week for the hemp-based CBD oil producer Charlotte’s Web Holdings, Inc. On August 30, 2018, the company reported the successful closing of its previously announced initial public offering (IPO), as well as a secondary offering of its common shares. Charlotte’s Web […]

By J.J. McCoy, Senior Managing Editor for New Frontier Data To read or hear the headlines through mainstream media these days, one thing that most Americans can agree on is that the U.S. economy is experiencing its best shape in decades. Hiring is robust with low unemployment, households and businesses are feeling optimistic, and stocks in […]